A Phase 2 Trial of the Combination of Polatuzumab Vedotin Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma

Brief description of study

The purpose of the study is to evaluate the activity of a novel triplet combination of rituximab and hyaluronidase human, polatuzumab vedotin, and venetoclax for relapsed Mantle Cell Lymphoma (MCL) patients. We want to know how patients respond to treatment with the regimen of rituximab and hyaluronidase human + polatuzumab vedotin + venetoclax (RSC+Pola+Ven) in relapsed/ refractory MCL. During the study, we also want to find out the best response in patients who continue on to maintenance therapy and evaluate the improvement in the depth of response.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.